002390 信邦制药
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,263,352-12.34%5,619,5656,032,2626,460,8416,350,026
减:营业总成本1,191,142-13.61%5,295,4625,712,4736,029,9576,015,574
    其中:营业成本1,058,664-12.47%4,627,8384,996,3685,232,2655,133,065
               财务费用2,686-32.87%12,45016,60327,75338,979
               资产减值损失----(21,675)(3,986)(7,523)--
公允价值变动收益------------
投资收益1,035920.68%19,7402,9279,39737,427
    其中:对联营企业和合营企业的投资收益------------
营业利润75,81422.74%237,278254,847385,033316,323
利润总额76,27124.84%229,965185,501396,022313,394
减:所得税费用11,71461.94%38,16929,81142,24945,138
净利润64,55819.86%191,796155,690353,773268,255
减:非控股权益15,90126.03%71,51054,30866,54043,881
股东净利润48,65617.97%120,286101,382287,233224,374

市场价值指针
每股收益 (元) *0.02618.43%0.0630.0530.1500.120
每股派息 (元) *----0.0900.0600.0600.060
每股净资产 (元) *3.5181.29%3.4933.4523.5253.503
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容